Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01841736 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 651 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Sep 10, 2026 to Sep 10, 2027 Secondary endpoints: details revised at 4 of 4 entries · Site details revised at 30 of 423 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised at 30 of 423 sites
  2. Study sites revised (423)v650 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (423)v649 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 424 to 423v648
  5. Study sites revised (424)v647 See this version in full on ClinicalTrials.gov ↗
Show 45 earlier versionsHide 45 earlier versions
  1. Re-verified, no change to tracked fieldsv646
  2. Study sites revised (424)v645 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 1 of 424 sitesv644
  4. 28 versions Re-verified since Feb 11, 2026, no change to tracked fieldsv616-v643
  5. Study sites revised (424)v615 See this version in full on ClinicalTrials.gov ↗
  6. Study sites: 426 to 424v614
  7. Study sites: 427 to 426 Completion date: Sep 13, 2025 to Sep 10, 2026v613 Show 1 more changeShow less
    • Completion date: Sep 13, 2025 to Sep 10, 2026
  8. Study sites: 428 to 427v612
  9. Re-verified, no change to tracked fieldsv611
  10. Study sites revised (428)v610 See this version in full on ClinicalTrials.gov ↗
  11. Study Status, Outcome Measures, Outcome Measures (Results), Adverse Eventsv609
  12. Interventions: Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography (Procedure), Laboratory Biomarker Analysis (Other)… to Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography Test (Procedure), Laboratory Biomarker Analysis… Study sites revised (428)v608 Show 1 more changeShow less
    • Study sites revised (428)

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites revised (428)v607 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (428)v606 See this version in full on ClinicalTrials.gov ↗
  15. Study Status, Contacts/Locationsv605
  16. 2 versions Re-verified since Feb 26, 2025, no change to tracked fieldsv603-v604
  17. Site details revised at 1 of 428 sitesv602
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT01841736
Lead Sponsor National Cancer Institute (NCI)
Conditions Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Enrollment 171 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov